GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Q32 Bio has built its reputation on a diverse pipeline targeting inflammatory conditions, with a particular focus on two key assets: ADX-914 (bempikibart) and ADX-097. The company's strategic approach ...

Q32 Bio has built its reputation on a diverse pipeline targeting inflammatory conditions, with a particular focus on two key assets: ADX-914 (bempikibart) and ADX-097. The company's strategic ...

US biotech Q32 Bio released Ph IIA trial results for its bempikibart for alopecia areata that were described as “messy,” sending the firm’s shares plunging 75%. Keros Therapeutics was another big ...

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart one in atopic dermatitis (AD or ...

The revision follows Q32 Bio's recent disclosures concerning its clinical trials, particularly the mixed results for its drug candidate, bempikibart. Q32 Bio recently reported negative results for ...

The company announced top-line results from the SIGNAL-AA Phase IIa signal finding clinical trial evaluating bempikibart (ADX-914), which identified encouraging clinical activity in patients with ...